Literature DB >> 12639083

Evaluation of 21st-century risks of smallpox vaccination and policy options.

J Michael Lane, Joel Goldstein.   

Abstract

The United States stopped vaccinating against smallpox in 1972 because the risks were judged to outweigh the benefits. The possibility of a terrorist attack using smallpox has led to renewed interest in a vaccination program. Smallpox vaccination carries considerable risks, which may be of greater concern today than in the late 1960s because of the increased prevalence of immunosuppression and atopy in the population. This paper reviews the clinical presentations of major adverse events after vaccination and the rates of occurrence of these events observed in the 1960s. The normal dynamics of the spread of smallpox is slow, and usually only persons who have had close personal contact with an overtly ill patient are affected. There are several preattack vaccination policy options, but immunization of medical workers, especially those who might have close contact with infected patients, is sufficient in the absence of a known threat of a bioterrorist attack or the identification of a smallpox-infected person.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639083     DOI: 10.7326/0003-4819-138-6-200303180-00014

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  26 in total

1.  Failure of the smallpox vaccine to develop a skin lesion in vaccinia virus-naïve individuals is related to differences in antibody profiles before vaccination, not after.

Authors:  Xiaolin Tan; Sookhee Chun; Jozelyn Pablo; Philip Felgner; Xiaowu Liang; D Huw Davies
Journal:  Clin Vaccine Immunol       Date:  2012-01-18

2.  Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.

Authors:  Shawn S Jackson; Petr Ilyinskii; Valérie Philippon; Linda Gritz; Alicia Gómez Yafal; Kimberly Zinnack; Kristin R Beaudry; Kelledy H Manson; Michelle A Lifton; Marcelo J Kuroda; Norman L Letvin; Gail P Mazzara; Dennis L Panicali
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

3.  Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Authors:  Janie Parrino; Lewis H McCurdy; Brenda D Larkin; Ingelise J Gordon; Steven E Rucker; Mary E Enama; Richard A Koup; Mario Roederer; Robert T Bailer; Zoe Moodie; Lin Gu; Lihan Yan; Barney S Graham
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

4.  Comparison of smallpox outbreak control strategies using a spatial metapopulation model.

Authors:  I M Hall; J R Egan; I Barrass; R Gani; S Leach
Journal:  Epidemiol Infect       Date:  2007-01-12       Impact factor: 2.451

5.  The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.

Authors:  Jonathan S Duke-Cohan; Kristin Wollenick; Elizabeth A Witten; Michael S Seaman; Lindsey R Baden; Raphael Dolin; Ellis L Reinherz
Journal:  Vaccine       Date:  2009-01-13       Impact factor: 3.641

6.  Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.

Authors:  Patricia L Earl; Jeffrey L Americo; Linda S Wyatt; Ondraya Espenshade; Jocelyn Bassler; Kathy Gong; Shuling Lin; Elizabeth Peters; Lowrey Rhodes; Yvette Edghill Spano; Peter M Silvera; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-04       Impact factor: 11.205

7.  Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro.

Authors:  Kathy A Keith; William B Wan; Stephanie L Ciesla; James R Beadle; Karl Y Hostetler; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

8.  Laboratory confirmation of generalized vaccinia following smallpox vaccination.

Authors:  Cassandra D Kelly; Christina Egan; Stephen W Davis; William A Samsonoff; Kimberlee A Musser; Peter Drabkin; James R Miller; Jill Taylor; Nick M Cirino
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

9.  Characterization and use of mammalian-expressed vaccinia virus extracellular membrane proteins for quantification of the humoral immune response to smallpox vaccines.

Authors:  Alonzo D García; Clement A Meseda; Anne E Mayer; Arunima Kumar; Michael Merchlinsky; Jerry P Weir
Journal:  Clin Vaccine Immunol       Date:  2007-06-27

10.  Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.

Authors:  Kaori Shinoda; Linda S Wyatt; Kari R Irvine; Bernard Moss
Journal:  Virol J       Date:  2009-03-03       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.